Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies

• Published in: Abdominal imaging Vol. 46; no. 8; pp. 3579 - 3595
• Main Authors: Eisenbrey, John R., Gabriel, Helena, Savsani, Esika, Lyshchik, Andrej
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2021; Springer Nature B.V
• Subjects: Cancer; Carcinoma, Hepatocellular - diagnostic imaging; Carcinoma, Hepatocellular - therapy; Computed tomography; Contrast Media; Gastroenterology; Hepatocellular carcinoma; Hepatology; Humans; Imaging; Liver; Liver cancer; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - therapy; Magnetic Resonance Imaging; Medical diagnosis; Medicine; Medicine & Public Health; Neoplasm Recurrence, Local; Radiology; Special Section: HCC Treatment; Temporal resolution; Tumors; Ultrasonic imaging; Ultrasonography; Ultrasound; HCC; Transarterial embolization; Contrast-enhanced ultrasound; LI-RADS; Ultrasound; Ablation
• ISSN: 2366-004X; 2366-0058; 2366-0058
• DOI: 10.1007/s00261-021-03059-y

Hepatocellular carcinoma (HCC) is a global problem constituting the second leading cause of cancer deaths worldwide, thereby necessitating an accurate and cost-effective solution for managing care. Ultrasound is well poised to address this need due to its low cost, portability, safety, and excellent temporal resolution. The role of ultrasound for HCC screening has been well established and supported by multiple international guidelines. Similarly, contrast-enhanced ultrasound (CEUS) can be used for the characterization of focal liver lesions in high-risk populations, and standardized criteria for CEUS have been established by the American College of Radiology Liver Imaging Reporting & Data System (LI-RADS). Following HCC identification, CEUS can also be highly beneficial in treatment planning, delivery, and monitoring HCC response to locoregional therapies. Specific advantages of CEUS include providing real-time treatment guidance and improved diagnostic performance for the detection of residual tumor viability or recurrence, thereby identifying patients in need of retreatment substantially earlier than contrast-enhanced CT and MRI. This review provides a primer on ultrasound and CEUS for the screening and characterization of HCC, with an emphasis on assessing tumor response to locoregional therapies.